Dr. Franz Obermayr is Co-founder and serves as Chief Executive Officer of Panoptes.
Before that he was Head of Clinical Development at Nabriva Therapeutics developing a novel antibiotic agent.
Before that he held several positions at GPC-Biotech where he led development programs in Germany and US and played a key role in commercialization these programs with pharmaceutical companies.
Prior to GPC-Biotech he did his postdoctoral studies at the Max-Planck Institute for Immunobiology. Franz earned his PhD in Biochemistry at the Imperial Cancer Research Fund in London.